
|Videos|September 29, 2022
Dr. Arora on the Evolution of Treatment in Follicular Lymphoma
Author(s)Madan L. Arora, MD
Madan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.
Advertisement
Madan L. Arora, MD, clinical associate professor, medicine, Michigan State University, College of Human Medicine, discusses the evolution of treatment in follicular lymphoma.
Significant progress has been made in the treatment landscape for patients with follicular lymphoma, with the addition of several new agents, Arora says. This multitude of available options has improved the overall survival of patients, Arora adds.
Patients are now able to receive a fixed duration of therapy that has led to prolonged survival for a majority of patients while maintaining a reasonable quality of life, Arora concludes.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































